市場調查報告書
商品編碼
1258198
2022-2029 年全球血漿蛋白治療市場規模研究與預測按產品類型,應用和地區分析Global Plasma Protein Therapeutics Market Size study & Forecast, by Product Type, by Application and Regional Analysis, 2022-2029 |
2021 年全球血漿蛋白治療市場價值約為 274,5 億美元,預計在 2022-2029 年預測期內將以超過 7% 的健康增長率增長。
血漿蛋白製品是由血漿組成的生物藥品。 血漿是一種生物材料,根據其製造和加工方式的不同,其化學成分也不同。 血液主要由血漿組成,含有水,鹽,蛋白質,抗體和□。 由於免疫缺陷病發病率增加和老年人口快速增長等因素,血漿蛋白市場正在擴大。 由於免疫缺陷疾病增加和人口老齡化等因素,血漿蛋白市場正在擴大。
血漿蛋白用於治療各種慢性,危及生命和遺傳性疾病。 它的受歡迎程度在過去幾年中逐漸增加。 據 Statista 稱,到 2020 年,全球血漿需求預計將增長 5000 萬升。 此外,到 2020 年,全球將消耗 1018,8 公噸白蛋白,預計到 2022 年將達到約 1125,5 公噸。 它是世界上用於癌症診斷和治療的血漿產生的蛋白質,以及莫布斯·威爾遜的治療方法。 主要用於癌症的診斷和治療。 推動空間增長的另一個關鍵因素是不斷增長的老齡化人口。 到 2022 年,摩納哥 65 歲及以上人口占總人口的比例將最高。 摩納哥是世界上人口老齡化速度最快的國家,其中 36% 的日本人超過 65 歲。 到 2022 年,德國將有 22% 的人口超過 65 歲。 世界上大約 25% 的人口年齡在 15 歲以下,10% 的人口年齡在 65 歲以上。 世界上最年輕的人口在非洲。 許多國家的預期壽命也很低,40% 的人口年齡在 15 歲以下,65 歲以上的人口不到 4%。 另一方面,在歐洲,65 歲及以上的人口多於 15 歲以下的人口。 2021年,百特國際宣佈在全球推出PrisMax2。 它旨在簡化連續腎臟替代療法和器官支持血漿療法的實施,並提供靈活性以滿足重症監護病房的需求。 PrisMax 2 具有我們的 TrueVue 數字健康產品組合和 PrismaLung 血氣交換器,可提供體外 decaprulation 治療以支持急性呼吸功能障礙。 然而,血漿蛋白產品的高成本將阻礙整個 2022-2029 年預測期內的市場增長。
全球血漿蛋白產品市場研究考慮的主要區域是亞太地區,北美,歐洲,拉丁美洲和世界其他地區。 由於醫療保健支出增加,北美在收入方面佔據主導地位。 根據 Statista 的數據,北美醫療保健行業預計 2023 年將達到 207,7 億美元,2023 年至 2027 年的年增長率為 12,25%,預計 2027 年市場規模將達到 329,7 億美元,預計將達到美元,
本研究的目的是闡明近年來各個細分市場和國家/地區的市場規模,並預測未來幾年的市場規模。 該報告旨在捕捉被調查國家行業的定性和定量方面的情況。
它還提供了關鍵方面的詳細信息,例如決定市場未來增長的驅動因素和挑戰。 此外,它還包含供利益相關者投資的潛在微觀市場機會,以及對主要參與者的競爭格局和產品供應的深入分析。
Global Plasma Protein Therapeutics Market is valued at approximately USD 27.45 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7% over the forecast period 2022-2029. Plasma protein therapeutics is a biological medicine made up of plasma. It is a biological substance with a distinct chemical composition depending upon how it was produced and processed. The majority of blood is made up of plasma, contains water, salts, proteins, antibodies, and enzymes. The Plasma Protein Therapeutics market is expanding because of factors such as increasing incidence of immune deficiency disorder and surge in geriatric populations. Its prevalence has progressively increased during the last few years.
Plasma protein therapies are used in the treatment of various chronic, life-threatening, and genetic diseases. Its prevalence has progressively increased during the last few years. According to Statista, plasma demand around the world was expected to increase up to 50 million liters by 2020. Furthermore, in 2020, more than 1018.8 metric tons of albumin were consumed worldwide and projected to reach around 1125.5 metric tons by 2022. It is a global protein generated from blood plasma used for cancer diagnostics and therapies, and Morbus Wilson treatments. It is used mostly for cancer diagnostics and therapies. Another important component driving space is increasing geriatric populations. In 2022, Monaco was the country with the highest percentage of total population that was over the age of 65. Monaco has the oldest population in the world with 36 percent of Japanese over 65. Germany on the other hand has 22 percent of its population being over 65 in 2022. In addition Approximately 25% of the world's population is under 15, while 10% is over 65. The youngest population in the world is found in Africa. Indicating the low life expectancy in many nations, 40% of people on the continent are under the age of 15 and less than 4% are over 65. Contrarily, in Europe, a greater proportion of the population is over 65 than is under 15 years old. Furthermore, in 2021 Baxter International Inc. announced the global launch of PrisMax 2. It is designed to simplify delivery of continuous renal replacement therapy and organ support plasma therapies, while providing flexibility to meet the demands of the intensive care unit . The PrisMax 2 system features the company's TrueVue digital health portfolio, as well as the PrismaLung blood-gas exchanger that delivers extracorporeal carbon dioxide removal therapy to support acute respiratory dysfunction. However, the high cost of Plasma Protein Therapeutics stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Plasma Protein Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the space in terms of revenue, owing to the dominance of increase in healthcare expenditure. According to Statista, the Health Care segment of north America is projected to reach USD 20.77 billion in 2023 and expected to show an annual growth rate of 12.25% in between 2023 to 2027, resulting in a projected market volume of USD 32.97 billion by 2027.Furthermore, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing research and development related to plasma protein therapies in the market space.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable